ArticleBMC cancer2023

Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study.

Xingsheng Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.